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Abstract 
Intratumor heterogeneity, which fosters tumor evolution, is a key challenge 
in cancer medicine. Here we review data and technologies that have 
revealed intra-tumor heterogeneity across cancer types, and the dynamics, 
constraints and contingencies inherent to tumor evolution. We emphasize 
the importance of macro-evolutionary leaps, often involving large-scale 
chromosomal alterations, in driving tumor evolution and metastasis, and 
consider the role of the tumor microenvironment in engendering 
heterogeneity and drug-resistance. We suggest that bold approaches to 
drug development, harnessing the adaptive properties of the immune-
microenvironment whilst limiting those of the tumor, combined with 
advances in clinical trial-design, will improve patient outcome. 
Introduction 
In a famous thought experiment, evolutionary biologist Stephen Jay Gould 
asked, if the ‘tape of life’ could be turned back to the very beginning, the 
same outcome would prevail (Gould, 2000). While re-playing the ‘tape of 
life’ remains a hypothetical experiment, the ‘tape of cancer’ is being played 
and re-played with increasing regularity and too frequently with lethal 
results. Cancer is one of the leading causes of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 cancer-related 
deaths occurring in 2012 alone (Siegel et al., 2013). Alarmingly, the number 
of new cases is predicted to rise by approximately 70% over the next two 
decades.  
 
A key factor contributing to the lethal outcome of cancer, therapeutic 
failure and drug resistance is intratumor heterogeneity (ITH) (Greaves, 
2015). ITH provides diverse genetic and epigenetic material upon which 
selection and Darwinian evolution can act. However, this diversity also 
permits the ‘tape’ of each cancer’s life to be deciphered, revealing the 
temporal order of genomic events and shedding light on constraints and 
contingencies to cancer evolutionary trajectories. The advent of next-
generation sequencing has enabled more powerful analysis of tumor 
evolution and has improved our understanding of tumor initiation and 
development, as well as the interaction between cancer cells and the 
immune-microenvironment. Despite these advances, knowledge of ITH and 
clonal evolution and the potential for competitive release of resistant 
subclones is infrequently considered in the therapeutic setting to inform 
clinical trial design.  
 
In this review, we explore the extent and clinical implications of ITH and 
discuss how profiling tumor genetic diversity has been used to trace 
tumors’ life histories and their patterns of evolution. We emphasize the 
importance of viewing tumor development in the context of an 
evolutionary framework, which includes large-scale genomic alterations, 
and consider the dynamic evolution of tumor cells and their interaction 
with the microenvironment. Finally, we outline approaches to address 
cancer systemically, taking into account ITH and tumor evolution.  
Intra-tumor heterogeneity: patterns and prevalence 
How much heterogeneity is there?  
Genomic diversity within single tumors has long been recognized. Indeed, 
as early 1958, evolutionary biologist Julian Huxley commented on ‘genetic 
inhomogeneity’ in cancer, noting, “it will be of great interest to discover 
the extent of such new variance and the rate at which it occurs” (Huxley, 
1958). However, it is only with the advent of next-generation sequencing 
studies that the full extent of genomic ITH is becoming apparent. 
Sequencing of spatially and/or temporally distinct tumor regions has 
begun to uncover the bewildering extent of diversity within tumors (Figure 
1). 
 
These studies have revealed that the degree of ITH can be highly variable, 
with between 1 to over 8000 thousand coding mutations found to be 
heterogeneous within primary tumors or between primary and 
metastatic/recurrence sites (Johnson et al., 2014). Despite caveats regarding 
differences in sampling procedure, tumor stage, and sequencing depth, it 
is evident that certain tumor types, such as melanoma and lung cancer, 
harbor a significantly larger homogeneous coding mutational burden than 
other types. The involvement of powerful exogenous mutagens, such as 
ultraviolet light and tobacco carcinogens, which a stem cell niche may be 
exposed to for years prior to the first invasive step, likely explain the 
elevated clonal mutational burden in these cancers (Alexandrov et al., 
2013). Accordingly, the prevalence of different types of base-substitutions 
(within a trinucleotide context) observed in these tumors reflect their 
exogenous exposures (Alexandrov et al., 2013).  
 
It is also evident that a large clonal burden does not equate to a large 
subclonal burden, or vice versa. Predominantly this likely reflects the fact 
that distinct mutational processes may operate at different times in tumor 
evolution (de Bruin et al., 2014; McGranahan et al., 2015; Nik-Zainal et al., 
2012). Indeed, the most notable outliers with regard to high subclonal 
mutational burden, but low clonal burden, are low-grade gliomas that 
recur as glioblastomas after treatment with the alkylating agent 
temozolomide (Johnson et al., 2014; Kim et al., 2015). In this case, the 
abundance of subclonal mutations can be directly linked to therapy-
induced mutations that are compounded by loss of mismatch repair 
machinery. As more data accumulates, the impact of therapy on mutational 
load and ITH will likely become clearer.  
 
In other cancer types, such as non-small cell lung cancer (NSCLC) and 
bladder cancer, the presence of a large subclonal mutation burden can be 
attributed to the action of the APOBEC family of cytidine deaminases (de 
Bruin et al., 2014; McGranahan et al., 2015; Zhang et al., 2014). In colorectal 
and prostate cancers, alterations to mismatch repair or proofreading 
machinery can occasionally play a key role in generating both clonal and 
subclonal mutations (Kumar et al., 2016; Uchi et al., 2016). 
 
Consistent with results from mathematical modeling (Tomasetti et al., 
2013), these studies also suggest that the clonal mutation burden in 
certain cancer types, including lung cancer and melanoma, predominantly 
reflects mutations accumulated prior to carcinogenesis, while in others, 
mutation burden may be more reflective of somatic events occurring after 
tumourigenesis. As such, the mutation rate of a tumor cannot necessarily 
be inferred from a single biopsy and simply considering the proportion of 
heterogeneous mutations represents a poor surrogate for diversity (Figure 
1).  
 
Importantly, heterogeneity does not simply affect coding mutations. A 
multitude of epigenetic mechanisms, including DNA methylation, 
chromatin remodeling and post-translational modification of histones, can 
contribute to diversity within tumors (for a review see (Mazor et al., 2016)). 
Analysis of ITH in gliomas (Mazor et al., 2015) as well as prostate cancers 
(Aryee et al., 2013) and esophageal squamous cell carcinomas (Hao et al., 
2016) has suggested that the extent of ITH calculated from DNA 
methylation mirrors ITH measures captured at the genomic level.  
 Genomic copy number heterogeneity can also be extensive within tumors, 
to the extent that copy number ITH in clear cell renal cell carcinoma 
(ccRCC) mirrors the extent of copy number diversity between tumors 
(Martinez et al., 2013). Large-scale chromosomal alterations may have 
profound impact upon the genome, disrupting hundreds of genes and can 
be considered macro-evolutionary events (see below), which may be 
required for tumor transformation (Notta et al., 2016). Loss of genomic 
material through chromosomal instability may also contribute to 
mutational ITH (McPherson et al., 2016; Murugaesu et al., 2015), 
highlighting the importance of considering both copy number and 
mutation data when inferring the evolutionary history of tumors.  
 
Heterogeneity can reveal a tumor’s life history 
A tumor’s mutational catalogue represents a historical record of alterations 
that have accumulated during its life history. The heterogeneity present 
between cancer cells can be used to illuminate the temporal order of these 
events. Alterations identified in every sequenced cancer cell can be 
considered to form the trunk of a cancer’s somatic evolutionary tree, while 
subclonal mutations, present in only a subset of cancer cells, make up the 
branches (Figure 2). Further, the prevalence of subclonal mutations in 
different cancer cells can be used to infer the subclonal hierarchy of the 
tumor’s phylogeny.  
 
A plethora of bioinformatics tools have been developed to help decipher 
the temporal order of mutations and determine which are clonal or 
subclonal. The majority of tools focus on somatic point mutations, and 
either restrict the analysis to copy neutral regions of the genome or make 
the assumption that a single mutation will be present at the same copy 
number state in every cancer cell (Carter et al., 2012; Miller et al., 2014; 
Roth et al., 2014). While tools to infer copy number heterogeneity have 
also been developed (Ha et al., 2014; Shen and Seshan, 2016), more recent 
tools seek to combine copy number and mutational data (Fischer et al., 
2014; Jiang et al., 2016) and furthermore, attempt to infer evolutionary 
relationships between subclonal populations (Deshwar et al., 2015; Jiang et 
al., 2016). Relatedly, orthogonal tools to dissect heterogeneity by using 
data from single-cell sequencing have also been developed (Roth et al., 
2016).  
 
However, despite considerable advances, it is self-evident that even 
cutting-edge tools can only dissect the ITH within the sample(s) subject to 
sequencing. As such, our ability to distinguish truly clonal from pseudo-
clonal mutations thereby determine the true clonal and subclonal burder 
of alterations is largely dependent on the number of tumor regions 
sequenced (de Bruin et al., 2014; Yates et al., 2015), the depth and purity 
of what is sequenced, and, further, whether single-cell sequencing is also 
implemented (Roth et al., 2016).  
Driver alterations and heterogeneity  
Studies exploring ITH within solid tumors have demonstrated a tendency 
for established cancer genes to harbor clonal mutations (McGranahan et 
al., 2015). However, despite this tendency, even mutations in cancer genes 
can be present in only a subset of cancer cells within a tumor.  
 
Subclonal driver mutations can give an illusion of clonality due to sampling 
bias. Whole-genome sequencing of 33 pairs of medulloblastomas pre and 
post-therapy found the majority of putative drug targets identified pre-
treatment appeared clonal, but were revealed to be subclonal or absent at 
recurrence (Morrissy et al., 2016). Equally, ITH may lead to significant 
underestimates of the number of driver alterations present in a tumor. 
Analysis of 86 cases of diverse primary tumors and brain metastases 
revealed that in 53% of cases, putative drug targets, including PTEN and 
PIK3CA, were exclusively identified in the brain lesions and not in the 
primary tumor (Brastianos et al., 2015).  
 
Accumulating evidence suggests certain driver alterations may be more 
likely to be subclonal than others. Subclonal mutations in PIK3CA have 
been found in, among other cancer types, lung (de Bruin et al., 2014), 
breast (Yates et al., 2015), colorectal (Uchi et al., 2016), melanoma (Harbst 
et al., 2016), esophageal squamous cell carcinoma (Hao et al., 2016), ccRCC 
(Gerlinger et al., 2014a) and ovarian cancers (Bashashati et al., 2013). In 
keeping with these results, across 9 cancer types, mutations in the PI3K-
AKT-mTOR pathway were found to harbor a higher proportion of subclonal 
mutations compared to genes associated with RAS-MAPK pathway 
(McGranahan et al., 2015). However, other driver mutations exhibit a 
tendency to be clonal in certain cancer types but not others. Mutations in 
TP53 appear almost exclusively clonal in NSCLC (de Bruin et al., 2014; 
Zhang et al., 2014), esophageal adenocarcinomas (Murugaesu et al., 2015) 
and ovarian cancers (Bashashati et al., 2013), yet are often subclonal in 
ccRCC (Gerlinger et al., 2014a) and chronic lymphocytic leukemia (CLL) 
(Landau et al., 2013). Such differences may reflect the importance of 
epistasis in cancer evolution and are in agreement with findings that co-
occurrence and mutual exclusivity relationships between cancer driver 
alterations can vary extensively in different cancer types (Park and Lehner, 
2015).    
 
The subclonal nature of genomic driver alterations can have important 
clinical implications. A recent report demonstrated that two gastric cancers 
with high clonal amplification of FGFR2 responded to the FGFR inhibitor 
AZD4547. Conversely, the six tumors with low or subclonal amplification of 
FGFR2 did not respond (Pearson et al., 2016). In CLL, the presence of 
subclonal driver alterations is associated with decreased relapse free 
survival (Landau et al., 2013).  
Processes of cancer genome evolution, and evolutionary 
debates: 
Selection and neutral evolution in cancer 
“the fittest will survive, and a race will be eventually produced adapted to 
the conditions in which it lives”, (Wallace, 1867) 
 
Although originally framed in relation to the evolution of individual 
organisms within a population, the fundamental principles of Darwinian 
evolution, involving variation with differential fitness that is heritable, can 
be applied in the context of tumor evolution (Nowell, 1976). In this setting, 
the population of cancer cells are subject to selection and the genetic 
variation between these cells, influenced by endogenous and exogenous 
mutational processes, provides the fuel for selection to act (Figure 3).    
 
However, although heterogeneity is required for Darwinian evolution, 
positive selection does not necessarily lead to heterogeneity (Waclaw et al., 
2015). As such, the extent to which positive selection can account for the 
degree of ITH in tumors has been called into question (Ling et al., 2015; 
Williams et al., 2016). Specifically, while evidence for selection of driver 
events in cancer development, as well as the selection pressures imposed 
by therapy, are undisputed, following a ‘big-bang’ of diversity early in 
tumor evolution, ITH development can follow the laws of neutral growth 
(Sottoriva et al., 2015). In support of this, Williams and colleagues noted 
that, for a subset of tumors, the relationship between the number of 
subclonal mutations and their relative abundance was consistent with a 
neutral growth pattern rather than subclonal expansions (Williams et al., 
2016). Likewise, in an extensively sampled colorectal cancer the degree of 
heterogeneity appeared more consistent with neutral growth (Ling et al., 
2015), and lineage-tracing studies in mice have suggested ITH may emerge 
from a stem-cell hierarchy of cancer cells evolving under neutral evolution 
(Driessens et al., 2012).   
 
Further work is warranted to explore the temporal and spatial dynamics of 
clones in human tumors. Longitudinal sequencing data from CLL has 
demonstrated clonal dynamics and shifts in selection pressures even in the 
absence of therapy (Nadeu et al., 2016). Conceivably, during Darwinian 
evolution, both selection and neutral growth may operate simultaneously 
within the same tumor and this may alter dynamically over time. The 
observation that multiple different diversity measures in Barrett’s 
esophagus predict progression to esophageal adenocarcinoma (Maley et 
al., 2006; Merlo et al., 2010) is indicative that diversity may lead to 
selection of aggressive subclones, even without therapeutic selection 
pressures. Relatedly, the fact that cancer genes can harbor a statistically 
significant enrichment of subclonal mutations suggests a signal of selection 
can be present throughout tumor evolution (McGranahan et al., 2015). It 
remains an open question whether distinct clinical behaviors can be 
observed depending on the mode of tumor evolution, or whether the 
occurrence of neutral evolution and drift may limit the ability to predict a 
tumor’s next step (Lipinski et al., 2016).  
Contingency and convergence 
Using the ‘tape of life’ metaphor, Gould emphasized the importance of 
chance and unpredictability in the evolution of life on earth, suggesting 
the end result is causally dependent on antecedent steps, or ‘historical 
contingency’ (Gould, 2000).  
 
Examples of genetic contingency impacting upon the clinical course of the 
disease can be found in cancer evolution. The order in which the two 
driver events in JAK2 and TET2 are acquired in myeloproliferative disorders 
affects the clinical course of the disease (Ortmann et al., 2015). If a TET2 
mutation is acquired first, expansion of hematopoietic stem and progenitor 
cells occurs, blocking expansion of erythroid progenitors until cells acquire 
a JAK2 mutation. Conversely, if a JAK2 mutation is acquired first, 
megakaryocyte number increases, with no expansion of the hematopoietic 
stem and progenitor pool until a TET2 mutation is acquired. Patients 
acquiring a JAK2 mutation first are younger at disease onset and are more 
likely to present with polycythemia rubra vera and develop thrombosis 
than they are to develop essential thrombocythemia. The cell of origin may 
also have important consequences on the impact of identical somatic 
events. Despite the fact that it is possible to induce pancreatic 
adenocarcinoma and non-small cell cancers from the same initiating events 
(TP53 inactivation, coupled with KRAS activation), these tumors have been 
found to exhibit distinct metabolic requirements, making use of branched-
chain amino acids in different ways (Mayers et al., 2016).  
 
An alternative (and likely complementary) view of evolutionary 
convergence, advocated by Conway Morris and others, is encapsulated by 
Darwin discussing analogical variation, noting  “the common rule 
throughout nature is infinite diversity of structure for gaining the same 
end” (Darwin, 1859) and echoed nearly 150 years later by Conway Morris 
the “recurrent tendency of biological organization to arrive at the same 
solution” (Conway Morris, 2003).  
 
Evidence supporting both historical contingency and convergence towards 
the same solution is apparent from cancer evolutionary studies. Indeed, in 
germline VHL mutant carriers with synchronous renal cell carcinomas 
developing in the same patient, evidence for both contingency and 
convergence can be found; despite distinct secondary 3p loss of 
heterozygosity events and driver mutations in different cancers from the 
same patient, there was evidence for convergent PI3K signal transduction 
pathway activation (Fisher et al., 2014). 
 
There is also extensive evidence for convergence of both genotype and 
phenotype in cancer evolution. Indeed, the notion of cancer hallmarks, 
supports the occurrence of convergence in cancer evolution. Further, 
Conway Morris’s assertion that  “it matters little what our starting point 
may have been: the different routes will not prevent a convergence to 
similar ends” (Conway Morris, 2003), could be used to describe the 
tendency for a cancer stem cell transcriptome to derive on multiple 
occasions across multiple distinct tumor types (Chen and He, 2016).  
 
Moreover, convergence is frequently seen within individual tumors, termed 
parallel evolution, which, in the context of cancer, refers to the 
independent evolution of similar traits starting from a single ancestral 
clone. Campbell and colleagues reported two overlapping out of frame 
deletions in exon 6 of PARK2 in distinct pancreatic cancer metastases from 
the same patient (Campbell et al., 2010). Similarly, recurrent and 
independent acquisition of copy number events such as deletions in PAX5, 
ETV6 and CDKN2A have been described in acute lymphoblastic leukemia 
(ALL) within distinct subclones (Anderson et al., 2011). Recurrent disruption 
of the SWI/SNF complex or activation of the PI3K pathway through distinct 
mutations in mTOR, TSC1, PTEN and PIK3CA are frequently observed in 
different subclones from the same renal cancer (Gerlinger et al., 2014a; 
Gerlinger et al., 2012; Voss et al., 2014).  
 
As the resolution of cancer evolutionary analyses improves, the number of 
examples of parallel evolution increases, including but not limited to 
events involving EGFR in glioblastoma (Francis et al., 2014; Kim et al., 
2015), TP53 and ATRX in glioma (Johnson et al., 2014), activation of the 
MAPK pathway in multiple myeloma (Bolli et al., 2014; Melchor et al., 
2014), NOTCH1 and GNPTAB recurrent mutations in esophageal 
adenocarcinoma (Murugaesu et al., 2015), SMO mutations in 
medulloblastoma (Morrissy et al., 2016), distinct AR amplification events  in 
prostate cancer (Gundem et al., 2015), KMTD2D and CREBBP mutations in 
follicular lymphoma (Okosun et al., 2014) and PTEN and TP53 mutations, 
FGFR2 amplifications and RUNX1 deletions in primary breast cancer(Yates 
et al., 2015), as well as distinct CCNE1 amplifications in ovarian cancers 
(McPherson et al., 2016). In clear cell renal carcinoma, an early clonal event 
is 3p loss of heterozygosity, which appears to prime the tumor for second 
hits in SETD2, PBRM1 and BAP1 (all of which are encoded on chromosome 
3p) later in tumor evolution (Gerlinger et al., 2014a). Similarly, in breast 
cancer, three of the four parallel evolutionary events (TP53, PTEN and 
RUNX1) documented by Yates and colleagues occurred as the second hit, 
following a clonal event (Yates et al., 2015).  
 
During the selection pressures of targeted therapies, parallel evolution 
driving polyclonal acquired drug resistance has been frequently 
documented. For example, in 13/16 patients with BRAF-mutant melanomas 
with resistance to RAF inhibition, multiple parallel mechanisms of resistance 
were observed (Shi et al., 2014). Likewise, following EGFR monoclonal 
antibody therapy, multiple KRAS mutations have been observed in 
circulating free DNA (Bettegowda et al., 2014; Misale et al., 2012). One 
patient acquired a codon 12 KRAS, codon 61 KRAS and a codon 61 NRAS 
mutation together with a BRAF codon 600 mutation following acquired 
resistance to EGFR monoclonal antibody therapy that were not detectable 
prior to therapy (Bettegowda et al., 2014). Following acquired resistance to 
a PI3K alpha inhibitor, Juric and colleagues found parallel evolution of 6 
distinct PTEN aberrations across 10 metastatic sites on the background of 
a clonal single copy PTEN deletion, reminiscent of second hit tumor 
suppressor gene loss following an early clonal event witnessed in breast 
and renal cancers (Juric et al., 2015).  
 
These observations suggest that despite the stochastic nature of genomic 
change, microenvironmental, epistatic and lineage constraints operate that 
might allow the prediction of a limited set of subsequent evolutionary 
moves.  
Gradualism versus punctuated evolution  
Another longstanding evolutionary debate that has reemerged in the context 
of tumor development centers on whether tumor evolution occurs gradually, 
through the sequential accumulation of mutations and clonal expansions, or, 
whether it is characterized by punctuated bursts (Figure 3). Such a dichotomy 
has been framed in the context of micro- versus macro- evolution, with 
gradual accumulation of point mutations (micro-evolution) presented in 
opposition to a saltationist view, which emphasizes the importance of large-
scale chromosomal alterations and bursts of mutations (macro-evolution) 
(Gerlinger et al., 2014b).  
 
An incremental, gradual, accumulation of mutations during the life history of a 
tumor is evidenced by the presence of clock-like mutational signatures that 
correlate with the chronological age of the patient (Alexandrov et al., 2015). 
However, not all mutations accumulate in a clock-like manner. In several 
cancer types (Alexandrov et al., 2013), a phenomenon termed kataegis has 
been observed; describing a small localized mutational process that results in 
hyper-mutation (a few to several hundred C>T and/or C>G substitutions, 
enriched at TpC sites) on the same DNA strand. A punctuated mode of tumor 
evolution is also supported from lineage tracing studies. Graham and 
colleagues used lineage-tracing techniques based on nuclear and 
mitochondrial DNA lesions in human colon adenomas to identify stem cell 
populations within adenoma crypts with multipotent potential and map 
their evolution over time. A punctuated model of rare clonal expansions 
interspersed with prolonged periods of stasis was suggested (Humphries et 
al., 2013).  
 
Cancer evolution is conceptually similar to evolution in asexually reproducing 
organisms, and in yeast it was recently demonstrated that tetraploid strains 
showed faster adaptation to a poor carbon source and accumulated more 
genomic diversity compared to diploid counterparts (Selmecki et al., 2015). In 
cancers, genome doublings have been estimated to occur at high frequencies 
(Zack et al., 2013), and are also associated with elevated rates of 
chromosomal aberrations (Dewhurst et al., 2014; Fujiwara et al., 2005; Zack 
et al., 2013). Genome doublings may serve to reduce the impact of Muller’s 
ratchet, a process by which asexual genomes accumulate deleterious 
mutation in an irreversible manner. Specifically, although the impact of a 
deleterious mutation cannot be removed through sexual reproduction, it can 
be mitigated by the presence of additional, doubled, wild-type alleles. 
 
Chromothripsis, characterized as a single catastrophic event resulting in tens 
of hundreds of locally clustered rearrangements affecting one or a few 
chromosomes, has also been documents to be widespread in cancers, 
occurring in over 30% of bladder cancers (Morrison et al., 2014), lung 
adenocarcinomas (Malhotra et al., 2013), oesophageal adenocarcinomas 
(Nones et al., 2014), glioblastomas (Malhotra et al., 2013), uterine 
leiomymoas (Mehine et al., 2013) and pancreatic cancers (Notta et al., 2016). 
These events occurred both clonally and subclonally during tumor evolution. 
Single-nucleus sequencing of 1000 cancer cells from 12 triple-negative breast 
cancers found evidence for copy number alterations that had accumulated in 
short punctuated bursts early in tumor evolution, but not late (Gao et al., 
2016). The progression of esophageal adenocarcinomas from Barrett’s 
esophagus is thought to involve a punctuated path whereby a TP53-mutant 
cell undergoes a whole genome doubling event, followed by the acquisition of 
oncogenic amplifications (Stachler et al., 2015), conceivably through 
chromothripsis (Nones et al., 2014).   
 
Chromothripsis and large-scale genomic rearrangements have parallels with 
evolutionary biologist Richard Goldschmidt’s notion of ‘hopeful monsters’ and 
‘macromutations’ (Goldschmidt, 1982). Such mutations were described as ‘of 
the most extraordinary rarity to provide the world with the important 
material for evolution" and appear analogous to the simultaneous 
disruption of multiple pre-neoplastic driver events (CDKN2A, TP53 and 
SMAD4) in single chromothriptic event in prostate cancer (Notta et al., 
2016).  
 
Perhaps unsurprisingly, while large-scale genomic rearrangements and 
chromothriptic events are often associated with aggressive cancers, its 
common occurrence in uterine leiomymoas highlight that it can also be 
involved in the development of benign tumors. In fact, consistent with 
“hopeful” and “hopeless monster” evolutionary thought, chromothripsis can 
even occasionally have a positive impact on patient outcome. McDermott and 
colleagues reported a case-study in which a chromothriptic event resulted in a 
cure for a patient with an inherited immunodeficiency disease caused by over-
activity of a mutated chemokine receptor CXCR4 (McDermott et al., 2015). 
Specifically, the chromothriptic event led to deletion of the aberrant allele in a 
single hematopoietic stem cell, which subsequently repopulated the bone 
marrow and restored normal immune function.  
 
Taken together, these data highlight the frequent occurrence of macro-
evolutionary events in cancers. However, temporal and multi-regional tumor 
analyses will be required to reveal the true extent to which chromosomal 
alterations occur dynamically throughout tumor evolution. Nevertheless, 
notably even static measures of aneuploidy are associated with poor 
prognosis across cancer types (McGranahan et al., 2012). Moreover, the 
observation that tumors with an extreme level of chromosomal instability 
appear associated with improved prognosis compared to intermediate levels 
(Andor et al., 2016; Birkbak et al., 2011), further supports the hypothesis there 
may be a delicate balance between too much and too little instability and that 
there may be potent selection pressures in cancer evolution for a “just-right” 
level of cell-to-cell variarion. 
Speciation and the metastatic process in cancer  
Tumor metastasis is frequently cited to be responsible for approximately 
90% of all cancer-related deaths. The process has been likened to a 
speciation event with macro-evolutionary leaps required to endow a tumor 
cell with metastatic potential (Gerlinger et al., 2014a; Turajlic and Swanton, 
2016).  
 
In certain tumors metastatic spread has been found to be monophyletic, 
with a single subclone in the primary tumor appearing to seed multiple 
metastases at different sites, resulting in low inter-metastatic ITH 
(McPherson et al., 2016; Schwarz et al., 2015). However, in other tumors, 
subclones at distinct metastatic sites are more closely related to subclones 
within the primary tumor than they are to each other, indicative of a 
polyphyletic metastatic process. Importantly, polyphyletic metastatic spread 
suggests multiple distinct evolutionary trajectories within a single tumor 
can result in metastatic dissemination. A study of seven patients with 
ovarian cancer found five patients exhibited monoclonal and uni-
directional seeding from the ovary to intraperitoneal sites, while the 
remaining two patients exhibited polyphyletic spread and reseeding 
(McPherson et al., 2016). However, convergent selection pressures in the 
metastatic setting, even in the context of polyphyletic spread, is evidenced 
by the occurrence of parallel evolution at distinct metastatic sites 
(Campbell et al., 2010). Finally, multiple rounds of metastasis, involving re-
seeding, may also occur, highlighting the diverse patterns of metastatic 
spread that can occur, even within single tumors (Turajlic and Swanton, 
2016).  
 
Lineage tracing studies have informed our understanding of the patterns 
of tumor metastatic seeding. In an autochthonous model of mouse 
pancreatic cancer Maddipati and colleagues used multi-color lineage 
tracing strategies to track early development of KRAS/p53 mutant 
pancreatic pre-invasive lesions through to metastatic disease (Maddipati 
and Stanger, 2015). Each pancreatic mass contained an average of four 
single color lesions, indicating the presence of distinct tumors originating 
from independent genetic events in the pancreas. A quarter of pre-
malignant precursor pancreatic lesions, acinar-to-ductal metaplasias 
(ADMs), displayed heterogeneous colors, indicative of their evolution from 
multiple acinar cells. However, pancreatic intra-epithelial neoplasia (PanIN) 
lesions displayed single colors, indicative of a bottlenecking event in the 
evolution of the pre-malignant disease from ADMs to PanIN lesions. 
Analysis of metastatic lesions in the lung, liver and peritoneum revealed a 
high frequency of polyclonal metastasis suggesting potential cooperativity 
between cancer subclones facilitating metastatic colonization. Evidence for 
polyclonal seeding of metastases was also observed in a common mouse 
model of breast cancer (Cheung et al., 2016). Supporting a clonal 
cooperativity model of tumor metastases, the authors found evidence for 
collective invasion and migration of polyclonal clusters of cells within the 
circulation seeding polyclonal disease at metastatic sites. These data reflect 
reports of circulating tumor cell clusters associated with poor prognosis in 
breast and prostate cancer (Aceto et al., 2014), and highlight the need to 
view cancer as an ecosystem of subclones that may act cooperatively or 
antagonistically.  
The cancer ecosystem 
Functional cooperativity 
The common occurrence of ITH challenges the view that tumor 
phenotypes are entirely driven by the dominant tumor clone in a cell-
autonomous manner, in which driver mutations only confer a benefit to 
the cancer cell in which they occur. If cancer cells act in a non-cell 
autonomous way, whereby driver mutations confer benefits to neighboring 
cells it will result in ITH and cooperative or social networks governing 
tumor behavior.  
Anton Berns and colleagues studied metastatic potential in a mouse model 
of small cell lung carcinoma (Calbo et al., 2011). Mesenchymal and 
neuroendocrine cells derived from a common progenitor, when engrafted 
into mice as a heterogeneous population triggered metastatic behavior of 
the neuro-endocrine cells.  In adult GBM, Inda and colleagues noted that 
EGFRvIII deletion mutants account for a minority of the total population in 
some tumors. The authors found a paracrine mechanism sustaining growth 
of the dominant EGFR wild type clones through IL-6 and/or LIF from the 
EGFRvIII deletion mutants leading to wtEGFR activation in neighboring 
clones, sustaining tumor heterogeneity (Inda et al., 2010).  
 
To investigate subclonal cooperativity further, Polyak and colleagues 
studied subclonal interactions in mouse xenograft models. Sub-populations 
of tumor cells could sustain the survival and growth of all tumor cells 
through IL-11 mediated microenvironment change. Notably, if minor 
subclones, sustaining the growth of the majority, were outcompeted by 
tumor subclones with greater proliferative capacity, tumor collapse 
resulted, suggesting non-cell autonomous drivers may be required for 
tumor development (Marusyk et al., 2014). Similarly, using a mouse model 
of breast cancer, Cleary et al (Cleary et al., 2014) demonstrated that clonal 
cooperation can be essential for tumor maintenance. Bi-clonal mouse 
tumors containing genetically distinct luminal and basal subclones were 
separated into their component subclonal populations and subsequently 
transplanted into wild-type host animals, either separately or as a 1:1 
admixture. Whereas the bi-clonal cell mixture was highly tumorigenic, 
mono-clonal populations failed to elicit tumor formation.  
 
Such cooperativity also extends to the field of drug resistance. Hobor and 
Bardelli noted that only a fraction of some cetuximab resistant colorectal 
cancer samples harbored KRAS mutations, commonly described to result in 
acquired resistance to EGFR directed therapies. The authors found evidence 
that TGF alpha and amphiregulin secretion from EGFR inhibitor resistant 
cells was capable of sustaining the growth of KRAS wild type drug sensitive 
cells in a paracrine manner (Hobor et al., 2014). 
 
The tumor microenvironment 
The tumor microenvironment likely imposes profound constraints upon 
cancer evolution both at primary and distant sites. Such constraints arise 
through resource limitations, immune predation and adverse growth 
conditions in the form of tissue hypoxia, acidosis and cancer therapeutics, 
amongst others. Increasing evidence supports the ability of tumor cells to 
shape their own advantageous growth environment and the ability of the 
microenvironment to protect tumor cells from the deleterious impact of 
exogenous sources of microenvironment change derived from systemic 
therapy. Therefore, cancer evolution cannot be fully understood without a 
detailed understanding of the source and impact of micro-environmental 
selection pressures. 
 
Computational, pathological as well as tumor imaging approaches are 
increasingly being used to describe the complex tumor microenvironment 
in a relatively unbiased manner. Aerts and colleagues applied radiomics, 
which refers to the quantification of tumor phenotype using multiple 
imaging features, to head and neck and lung cancers (Aerts et al., 2014). 
The authors found that multiple radiomic features associated with 
heterogeneity were linked to poorer survival outcome in both tumor types. 
Through the integration of gene expression and somatic copy number data 
with automated microenvironment analysis from standard hematoxylin and 
eosin slides, Yuan and colleagues demonstrated that survival predictions in 
ER negative breast cancer can be optimized (Yuan et al., 2012). The authors 
found that the spatial distribution of stromal cells was an independent 
prognostic factor for survival outcome. Similarly, in ovarian cancers the 
percentage of stromal cells (assessed from hematoxylin and eosin slides) 
was significantly associated with poor overall and progression free-survival, 
even after controlling for clinical parameters including surgical debulking 
status and age (Natrajan et al., 2016). In prostate cancers, a measure of 
genomic instability coupled with intratumoral hypoxia was found to be 
able to significantly improve prognostic accuracy, beyond conventional 
clinical parameters (Lalonde et al., 2014). A landmark study in melanoma, 
which sequenced over 4,500 single cells from 19 patients (including 
malignant, immune, stromal and epithelial cells), identified therapy 
resistance tumor subpopulations present prior to treatment, which may 
have been missed with bulk-sequencing, as well as a relationship between 
cancer-associated fibroblasts and preferential expression of an AXL-
high/MITF-low transcriptional program (Tirosh et al., 2016).  
 
Recently, approaches to analyze the tumor microenvironment in 3D have 
been developed, allowing a quantitative measure of micro-environmental 
heterogeneity to be assessed (ecosystem diversity index) (Natrajan et al., 
2016). In grade 3 breast cancers, high micro-environmental diversity was 
associated with poor prognosis, independent of tumor size or genomic 
features. The authors suggest these data are indicative of cooperation 
between tumor cells and the microenvironment.  Further, the spatial 
diversity of resources inherent in a heterogeneous tumor 
microenvironment may select for a metastatic phenotype. A 
complementary explanation is that a heterogeneous tumor 
microenvironment may also contribute to unequal drug penetration 
brought about by disordered blood vessel development that might 
contribute to resistant cell populations emerging through therapy (Fu et 
al., 2015; Junttila and de Sauvage, 2013) or to the development of diverse 
niches including hypoxic or perivascular regions that might support cancer 
stem cell phenotypes and chemo-resistance (Mao et al., 2013).  
 
Immune-mediated editing  
Seminal work from the Schreiber laboratory in mouse models 
demonstrated the capacity of the immune system to maintain tumors in a 
state of equilibrium, where clonal expansions are attenuated by adaptive 
immunity (Koebel et al., 2007). These observations begin to shed light on 
tumor dormancy and how patients with early stage breast cancer may have 
disseminated tumor cells in bone marrow, which never give rise to 
metastatic disease (Hartkopf et al., 2014). 
 
One substrate for immune-mediated disease control of tumor growth can 
be patient-specific neo-antigens that arise as a consequence of tumor-
somatic mutations. A number of studies have revealed an association of 
tumor mutational burden with response to immune checkpoint blockade. 
In both melanoma and non-small cell lung cancer, evidence is building 
that the mutational load and or neo-antigen burden correlates with benefit 
to anti-CTLA4 therapy in melanoma ((Snyder et al., 2014; Van Allen et al., 
2015)) and anti-PD1 therapy in NSCLC (Rizvi et al., 2015). Likewise, hyper-
mutated mismatch repair deficient tumors are significantly more responsive 
to immune-checkpoint blockade than their mismatch repair proficient 
counterparts (Le et al., 2015).  
 
How tumor cells evade such hostile immune predation is becoming an 
active research area. Hacohen and colleagues devised an RNA-seq based 
signature of cytolytic activity, incorporating Granzyme A and Perforin, 
genes which are up-regulated following CD8+ T cell activation (Rooney et 
al., 2015). Application of the signature to the TCGA dataset, revealed that 
certain tumors such as renal clear cell carcinoma exhibit high cytolytic 
activity  while others such as glioma and prostate cancer tend to display 
low cytolytic activity. Somatic mutations in specific genes, such as 
inactivating mutations in Caspase 8, were associated with higher cytolytic 
activity. These data are consistent with previous work revealing that 
Caspase 8 blockade results in tumor T cell escape in two murine tumor 
models (Medema et al., 1999).  CTL activity was associated with both the 
rate of mutations and the rate of mutations resulting in predicted neo-
antigens across multiple tumor types (Rooney et al., 2015). Intriguingly, 
colorectal and kidney cancer harbored significantly fewer putative neo-
antigens per non-silent than expected, consistent with immune-editing, 
where immune activity likely results in the depletion of emerging tumor 
clones with productive neo-epitopes. 
 
The evolving somatic mutational landscape may also influence immune 
surveillance and response to checkpoint blockade. Evidence is emerging 
that the clonal status of a neo-antigen might influence immune checkpoint 
benefit. Tumors with a high clonal neo-antigen burden and low subclonal 
neo-antigenic heterogeneity appeared to be enriched in patients 
benefiting from anti-PD1 therapy in NSCLC or anti-CTLA4 therapy in 
melanoma (McGranahan et al., 2016). Whether subclonal neoantigens 
developing in a rapidly evolving tumor actively distract the immune 
response from the effective targeting of clonal neo-antigens is unclear. We 
have recently shown that APOBEC-induced mutagenesis contributes to 
branched evolution and the acquisition of subclonal mutations in 
adenocarcinoma of the lung, ER negative breast cancer, head and neck 
squamous carcinoma and esophageal adenocarcinomas (de Bruin et al., 
2014; McGranahan et al., 2015; Rosenthal et al., 2016).  In this regard the 
parallels with HIV-based evolution of diversity mediated by APOBEC 
activity are intriguing.  Evidence suggests that APOBEC 3G/3F induced 
mutations in HIV are less immunogenic and reduce CD8+ T cell responses 
against common HIV epitopes ex vivo (Monajemi et al., 2014). Whether 
APOBEC induced mutagenesis provides the tumor with a similar immune 
evasion escape warrants further investigation. 
 
The dynamic nature of the “predator-prey” relationship between the 
immune microenvironment and the tumor has recently been highlighted 
by work demonstrating the ability of tumors to lose the expression of neo-
antigens (Anagnostou et al., 2016; Verdegaal et al., 2016). Thus, therapeutic 
efforts may have to be oriented towards the targeting of multiple clonal 
neo-epitopes to optimize disease control and minimize the potential for 
immune escape. 
Safe havens 
Recent studies have suggested mechanisms of tumor resistance need not 
always be mediated by the selection for resistant populations of tumor 
cells (Hirata et al., 2015).  
 
Using detailed intravital imaging in a mouse model of cancer, Sahai and 
colleagues have demonstrated that resistance to a BRAF inhibitor PLX4720 
is mediated through melanoma associated fibroblast induced matrix 
remodeling. This promotes integrin Beta 1-FAK-Src signaling within 
melanoma cells and reactivation of ERK signal transduction and BRAF 
inhibitor resistance that can be circumvented by combined BRAF/FAK 
inhibition. Consistent with these data, fibronectin matrices (Hirata et al., 
2015) or fibronectin induction (Fedorenko et al., 2016) are sufficient to 
circumvent the impact of BRAF inhibition on tumor cells. Co-cultures of 
fibroblasts, stromal cells and tumor cells revealed stromal derived HGF as a 
mediator of RAF inhibitor resistance in BRAF mutant melanoma cells via 
activation of its cognate receptor cMET (Straussman et al., 2012). 
Moreover, BRAF inhibition results in TGF beta release from melanoma cells, 
which promotes the differentiation of fibroblasts, fibronectin expression 
and HGF secretion which together triggers PI3K/AKT pathway activity 
(Fedorenko et al., 2016).  Similar evidence in the field of anti-angiogenic 
therapies implicates the stroma in resistance to therapy through release of 
PDGF-C by cancer-associated fibroblasts (CAFs) (Crawford et al., 2009).  
 Just as genotoxic damage can foster the emergence of drug resistant cells 
and histological transformation of the tumor into a high-grade recurrence 
(Johnson et al., 2014; Kim et al., 2015), the stroma can also be adversely 
affected by genotoxic agents to support the survival of cancer cells in the 
face of such selection pressures. Genotoxic therapy can promote the 
microenvironmental secretion of WNT16B that reduces the impact of 
cytotoxic therapy upon prostate cancer cells in vivo (Sun et al., 2012).  
Genotoxic chemotherapy can also result in secretion of IL-6 and TIMP-1 
from thymic endothelium in a mouse model of Burkitt’s lymphoma, which 
promotes the survival of minimal residual disease in the thymus (Gilbert 
and Hemann, 2010). Exploring this chemoresistant perivascular niche 
phenomenon further, Hodivala-Dilke and colleagues demonstrated that 
following DNA damage, FAK loss from endothelial cells sensitizes cancer 
cells to doxorubicin through the suppression of NF-kB induced cytokine 
production from endothelial cells and concomitant reduced phospho-
STAT3 in tumor cells following doxorubicin exposure, without having any 
measurable impact on endothelial function (Tavora et al., 2014). 
 
Finally, increasing evidence supports the ability of the immune 
microenvironment to support the survival of tumor cells. MAPK pathway 
inhibition increases macrophage infiltration into the tumor 
microenvironment, promoting resistance to BRAF and MEK inhibition 
through TNF alpha release from myeloid cells, mediated the induction of 
the melanocytic-specific transcription and survival factor, MITF (Smith et al., 
2014). 
 
Taken together, these data are in keeping with the concept that the 
microenvironment can provide a “safe haven” for the evolution of drug 
tolerant cells, providing an explanation as to how cells survive in the 
period between initial tumor response and disease progression. 
Conceivably, through this permissive microenvironment, tumor cells may 
proceed to acquire genetically encoded drug resistant mechanisms that 
might dominate specific lesions at progression. Targeting the 
microenvironment itself may therefore present an effective strategy to 
manage cancer clonal evolution. Using a humanized mouse model 
Bcl2/Myc driven lymphoma, treated with alemtuzumab (anti-CD52 
antibody), Hemann and colleagues demonstrated that infiltration of 
resistant leukemia cells into the bone marrow rewires the tumor 
microenvironment to inhibit engulfment of antibody-targeted tumor cells. 
Combination therapy of cyclophosphamide with the antibody eliminated 
residual disease by inducing a secretion phenotype that increased 
infiltration of macrophages into the bone marrow and enhanced 
phagocytic activity (Pallasch et al., 2014).  
Managing clonal evolution 
Despite extensive clinical data documenting ITH and its clinical relevance, 
drug development and novel clinical trial designs to account for the 
dynamic evolution of tumors have lagged behind. 
Longitudinal sampling strategies 
Given the evolutionary capabilities of tumors, monitoring disease evolution 
to guide therapeutic interventions and to understand evolutionary 
trajectories of individual tumors has become a vital research area. Serial 
sampling of tumor genomes from plasma and circulating tumor cells is 
now increasingly implemented in both clinical research settings to monitor 
cancer clonal evolution and drug resistance mechanisms over time (Haber 
and Velculescu, 2014) as well as the evolution of metastatic disease 
(Carreira et al., 2014). Sequencing of circulating tumor DNA (ctDNA) 
through therapy can reveal somatic mutations acquired at resistance 
following cytotoxic and targeted therapies (Murtaza et al., 2013) and the 
detection of which has higher sensitivity and dynamic range than 
conventional blood based markers (Dawson et al., 2013). Furthermore, an 
increase in ctDNA heralds progressive disease in advance of conventional 
imaging approaches (Dawson et al., 2013). 
 
Problems inherent to tumor sampling bias due to ITH may be mitigated 
with ctDNA sampling (Jamal-Hanjani et al., 2016; Russo et al., 2016; 
Siravegna et al., 2015). Moreover, such methods can track mechanisms of 
resistance to targeted agents, which may emerge during the course of 
therapy. Multiple mutations in KRAS and NRAS were identified in the same 
patient through BEAMing analysis of ctDNA, acquired during cetuximab or 
panitumumab exposure in advanced colorectal cancer, converging upon 
the reactivation of ERK signaling. These results suggest a rational strategy 
to limit acquired therapy resistance may be through dual blockade of both 
EGFR and MEK signaling (Misale et al., 2012). Studies are also revealing the 
dynamic clonal evolution that occurs subsequent to the acquisition of drug 
resistance. Bardelli and colleagues (Siravegna et al., 2015) demonstrated 
the waning of KRAS mutant subclones upon EGFR monoclonal antibody 
drug withdrawal, suggesting fitness costs following the acquisition of KRAS 
mutations later in tumor evolution and providing an explanation for further 
tumor responses following drug re-challenge. However, a drawback of 
ctDNA sampling strategies is that they cannot necessarily provide an 
accurate portrayal of the copy number state of the cancer genome nor a 
detailed phylogeny, and there may be over-representation of DNA from 
dying cells. In this respect, circulating tumor cells may provide additional 
information.   
Targeting clonal events 
Targeting clonal events, present in every tumor cell, may present an 
attractive model for drug development. Indeed, it is likely that many 
targeted therapies that have successfully passed through the drug 
development process, demonstrating robust progression free survival 
benefits in clinical trials, are targeting early clonal events present at all sites 
of disease. However, even in the context of a clonal driver, resistance to 
such therapies is frequent in the advanced disease setting and may be 
driven by the selection of resistance cancer cells present at low frequencies 
prior to therapy (Bhang et al., 2015; Su et al., 2012; Turke et al., 2010) or 
may evolve through de novo mutations that are acquired during therapy 
(Hata et al., 2016).  
 Modeling approaches have estimated that most lesions identifiable 
through radiographic techniques harbor ten resistant subclones (Bozic and 
Nowak, 2014). Combination therapy approaches that act through distinct 
pathways may help circumvent this problem (Bozic et al., 2013). However, 
in practice the feasibility of such approaches may be complicated by the 
toxicity of combination therapy, as well as the occurrence of mutations 
that confer resistance to multiple drugs.   
 
Conceivably, vaccine or adoptive T cell therapy approaches targeting 
multiple clonal neo-antigens may provide the specificity required to 
minimize normal tissue toxicity and maximize tumor cell kill, whilst 
minimizing the possibility for acquired drug resistance to occur. We have 
recently found evidence for CD8+PD1+ T cell populations recognizing 
clonal neo-antigens present in all cells of a tumor (McGranahan et al., 
2016). However, the extent to which tumors could circumvent such 
strategies through chromosomal instability-driven loss of neo-antigens 
remains unclear. 
Attenuating or exploiting genome instability 
Genome instability acts as a fuel for cell-to-cell variation and hence 
selection and evolution. The clinical relevance of genomic instability is 
evidenced by the association of chromosomal instability with outcome 
across multiple cancer types (McGranahan et al., 2012), and accumulating 
evidence linking chromosomal chaos with metastasis (Turajlic and Swanton, 
2016). Targeting specific genome instability mechanisms may provide a 
means to arrest tumor evolution and limit disease progression, particularly 
in the early disease.  
 
The success of PARP inhibitors in the treatment of BRCA-mutant cancers 
exemplifies how genomically unstable cancers can be targeted by elevating 
instability to lethal levels and exploiting synthetic lethality (Lord and 
Ashworth, 2016). However, even in this context resistance can occur, for 
example through BRCA reversion either directly through additional 
mutations to BRCA (Lord and Ashworth, 2016) or indirectly through, for 
example, inactivation of 53BP1(Lord and Ashworth, 2016).  
 
Maley and colleagues have explored the impact of non-steroidal anti-
inflammatory agents (NSAIDs) upon the evolution of pre-invasive Barrett’s 
esophagus to invasive esophageal cancer. In a longitudinal analysis of 13 
patients who had been exposed to NSAIDs over a period of several years, 
the authors found evidence that NSAID use was associated with a reduced 
rate of somatic genomic abnormalities as defined by SNP array analyses 
(Kostadinov et al., 2013). 
 
Evolutionary studies are revealing distinct mutagenic processes that occur 
through the disease course. Evidence is emerging in lung adenocarcinoma, 
bladder cancer, estrogen receptor negative breast cancer, head and neck 
squamous carcinoma and esophageal squamous carcinoma that APOBEC 
induced mutagenesis is enriched later in tumor evolution, suggesting that 
efforts to target the cytidine deaminase family may demonstrate utility to 
limit ongoing mutagenesis (de Bruin et al., 2014; McGranahan et al., 2015). 
A recent study, using clinical data and xenograft experiments, found 
evidence that APOBEC3B can facilitate tamoxifen resistance in ER-positive 
breast cancer (Law et al., 2016). Similarly, chemotherapy refractory 
chemotherapy-resistant urothelial carcinomas exhibited an enrichment of 
APOBEC3B mutations following therapy (Faltas et al., 2016). Inhibiting 
APOBEC3B may provide an effective strategy to improve efficacies of 
cancer therapies, by limiting the evolutionary potential of cancer cells.  
Competitive release and Adaptive Therapy 
Whilst benefits in progression free survival times are commonly reported in 
clinical trials, these rarely translate to equivalent clinically relevant overall 
survival benefits (Fojo et al., 2014). Notwithstanding the complexities of 
clinical trial design, the mismatch between progression free and overall 
survival times may reflect clonal competition and competitive release. 
Conceivably, elimination of a dominant drug sensitive clone in the 
investigational arm, might allow the competitive release of resistant 
subclones to undergo accelerated growth in a resource-rich environment, 
resulting in more rapid disease progression compared to the control arm 
after the observed progression free survival benefit (Figure 4).    
 
Thus, new trial concepts accounting for competitive release of resistant 
subclones may maximize the overall survival benefits with current 
therapies. Gatenby and colleagues have devised approaches in animal 
models to exploit the fitness cost of resistant subclones by maintaining a 
stable population of sensitive subclones, thereby restricting the growth of 
resistant cells (Enriquez-Navas et al., 2016). In contrast to standard clinical 
practice where the goals of therapy are to reduce tumor burden, the focus 
of adaptive therapy is to maximize time to progression by stabilizing tumor 
size (Enriquez-Navas et al., 2016; Gatenby et al., 2009). Adaptive therapy 
requires variable drug dosing and schedules in two phases; an induction 
phase to control tumor progression from exponential growth; and a 
maintenance phase that might require progressively lower dosing or even 
omitted schedules resulting in better progression free survival times 
compared to standard fixed dosing. In keeping with the benefits of an 
adaptive therapy approach, in the context patient-derived melanoma 
xenografts. Stuart and colleagues demonstrated how vemurafenib resistant 
melanomas can exhibit drug dependency, such that an intermittent rather 
than continuous dosing of the drug can forestall the onset of lethal drug 
resistance (Das Thakur et al., 2013). 
 
Exploiting evolutionary constraints.  
Traditional approaches to cancer management are primarily reactive, 
focusing on the management of drug resistant disease. Pro-active 
management of cancers through attempts to predict or attenuate a 
cancer’s next evolutionary move, exploiting evolutionary constraints or 
synthetic lethality, might be feasible as knowledge of evolution across 
cancer types increases.  
 
Emerging evidence in renal cell carcinoma suggests that the constraints 
upon activation of the PI3K/mTOR pathway, manifested as recurrent 
deleterious or activating mutations in PTEN, PIK3CA, TSC1 or mTOR, might 
be exploitable for therapeutic benefit. Voss and colleagues examined renal 
tumors from 5 patients who had experiences a prolonged benefit from 
mTOR pathway inhibition with Everolimus or Temsirolimus. Multi-region 
tumor sampling revealed parallel evolution with distinct somatic mutations 
predicted to lead to activation of the mTOR pathway in different tumor 
regions in 3 of the 5 cases (Voss et al., 2014). These data suggest that 
targeting constraints to tumor evolution might be practical if appropriate 
biomarker assays could be developed that could detect parallel evolution 
leading to signal transduction pathway convergence.  
 
A further tractable approach may be derived from exploiting iatrogenic 
evolutionary selection pressures. An approach termed “collateral sensitivity” 
leverages the phenomenon where resistance acquired to one drug comes 
at the expense of sensitivity to another (Hill, 1986; Jensen et al., 1997). 
Hemann and colleagues have exploited such evolutionary constraints in a 
murine model of Philadelphia chromosome positive acute lymphoblastic 
leukemia (ALL) (Zhao et al., 2016). The authors described collateral 
sensitivity induced by treatment with dasatinib, which resulted in the 
selection of the acquired resistance BCR-ABL1 V299L mutation at 
intermediate stages of evolution of Ph+ ALL cells. This rendered the cells 
sensitive to non-classical BCR-ABL inhibitors such as cabozantinib and 
vandetanib.  
 
Similar methods have been applied to the targeting of aneuploid 
populations. Rong Li and colleagues use an “evolutionary trap” by reducing 
karyotypic heterogeneity to a defined predictable state through initial drug 
exposure, which can then by targeted by a secondary drug. Specifically, 
exposure of aneuploid budding yeast to radicol, an HSP90 inhibitor, results 
in the selection of multiple copes of chromosome XV. Amplification of 
chromosome XV results in resistance to radical, however, it also engenders 
sensitivity to hygromycin (Chen et al., 2015).  
 
Evidence is emerging for the potential of similar strategies in the clinical 
setting. Engelman and colleagues explored resistance mechanisms in a 
patient with ALK rearranged non-small cell lung cancer with a subclonal 
C1156Y mutation in the kinase domain, acquired following progression on 
crizotinib (Shaw et al., 2016). Although the tumor did not benefit from a 
second generation ALK inhibitor, it did respond to the 3rd generation ALK 
inhibitor, lorlatinib. Following progression on lorlatinib, the tumor acquired 
a L1198F mutation, which, together with the pre-existing C1156Y alteration, 
prevented drug interaction with the kinase. However the L1198F mutation 
promoted re-sensitization to crizotinib, thereby resulting in improvement in 
the patient’s symptoms. This case study illustrates how evolutionary 
constraints and collateral sensitivity can be exploited for patient benefit. 
 
Conclusions 
Although our understanding of cancer genome evolution, and the dynamic 
interplay between tumor cells and the microenvironment, has dramatically 
increased, the field of cancer evolutionary therapeutics is still in its infancy. 
As we attempt to forecast evolution and proactively manage a dynamic 
tumor genome and its microenvironment, it is worth reflecting that Darwin 
recognized such challenges “throw up a handful of feathers, and all fall to 
the ground according to definite laws; but how simple is the problem 
where each shall fall compared to that of the action and reaction of 
innumerable plants and animals which have determined, in the course of 
centuries, the proportional numbers and kinds of trees now growing” 
(Darwin, 1859). Predicting the innumerable interactions of cancer subclones 
with each other and the microenvironment is an equally formidable task. 
Computational and technological advances, coupled with prospective 
longitudinal studies exploring the cancer genome and the immune 
microenvironment, will be needed to gain a deeper understanding of the 
evolutionary trajectories of tumors and the extent to which a tumor’s next 
step may be predicted. Such studies may also allow new insights into the 
processes generating diversity and reveal how constraints to tumor 
evolution may be exploited, leveraging an adaptive immune response, 
permitting proactive management of cancers.  
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Figure 1 Heterogeneity of non-silent mutations from multiple-sample 
sequencing across a range of cancer types.  For each tumor type, each 
point represents one tumor, with the proportion of heterogeneous 
mutations (ITH proportion), as well as the absolute numbers of 
heterogeneous and homogeneous non-silent mutations shown. Black 
circles represent treatment naïve tumors, with red triangles indicating 
tumors that have received treatment. Notably, this data is restricted to 
non-silent mutations and does not include copy number alterations. The 
data is extracted from the following primary publications: Diffuse intrinsic 
pontine glioma (Nikbakht et al., 2016); Neuroblastoma (Eleveld et al., 2015); 
low-grade gliomba/glioblastoma multiforme (Johnson et al., 2014; Kim et 
al., 2015; Wang et al., 2016); breast cancer (Yates et al., 2015); clear cell 
renal cell carcinoma (Gerlinger et al., 2014a); multiple myeloma (Bolli et al., 
2014); lung adenocarcinomas (de Bruin et al., 2014; Zhang et al., 2014); 
prostate (Gundem et al., 2015; Ju et al., 2014); bladder (Lamy et al., 2016); 
colorectal adenocarcinomas (Uchi et al., 2016); liver hepatocellular 
carcinoma (Xue et al., 2016); esophageal squamous cell carcinoma (Hao et 
al., 2016); ovarian (Bashashati et al., 2013; Eckert et al., 2016); esophageal 
adenocarcinoma (Murugaesu et al., 2015); melanoma (Harbst et al., 2016).  
 
 
Figure 1 Evolutionary trees illustrating intratumor heterogeneity across 
cancer types. For each cancer type, the mean number of clonal and 
subclonal non-silent mutations are depicted as trunks (blue) and branches 
(yellow and red) respectively.  
 
Figure 3 Clonal heterogeneity and tumor evolution: modes, 
mechanisms, ecosystems and evolutionary therapeutics. The first three 
panels depict different aspects of cancer genome evolution, which all need 
to be understood to develop improved evolutionary therapeutics (panel 
four).    
 
Figure 4 Competitive release of resistance subclones. Similar overall 
survival times, yet divergent progression free survival times, between 
treated and un-treated patients may reflect competitive release of 
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